HRS4R
Vull donar

YOLANDA GONZALEZ MONTES

Firma
YOLANDA GONZALEZ-MONTES
Posició
Investigador/a Pre-doctoral – R1
Investigadors/es Pre-doctorals – R1

Publicacions

Dimopoulos MA, Schjesvold F, Doronin V, Vinogradova O, Quach H, Leleu X, Montes YG, Ramasamy K, Pompa A, Levin MD, Lee C, Mellqvist UH, Fenk R, Demarquette H, Sati H, Vorog A, Labotka R, Du J, Darif M, Kumar S

Oral ixazomib-dexamethasone vs oral pomalidomide-dexamethasone for lenalidomide-refractory, proteasome inhibitor-exposed multiple myeloma: a randomized Phase? 2 trial.

BLOOD CANCER JOURNAL, 2022, 12, 9-9 dx.doi.org/10.1038/s41408-021-00593-2
0

Real-World Evidence of Daratumumab Monotherapy in Relapsed/Refractory Multiple Myeloma Patients and Efficacy on Soft-Tissue Plasmacytomas.

Clinical Lymphoma, Myeloma and Leukemia, 2022, 22, 635-642 dx.doi.org/10.1016/j.clml.2022.04.014

Chang-Chan DY, Ríos-Tamayo R, Rodríguez Barranco M, Redondo-Sánchez D, González Y, Marcos-Gragera R, Sánchez MJ

Trends of incidence, mortality and survival of multiple myeloma in Spain. A twenty-three-year population-based study.

CLINICAL & TRANSLATIONAL ONCOLOGY, 2021, 23, 1429-1439 dx.doi.org/10.1007/s12094-020-02541-1

Cejalvo MJ, Bustamante G, González E, Vázquez-Álvarez J, García R, Ramírez-Payer Á, Pérez-Persona E, Abella E, Garzón S, García A, Jarque I, González MS, Sampol A, Motlló C, Martí JM, Alcalá M, Duro R, González Y, Sastre JL, Sarrà J, Lostaunau G, López R, de la Rubia J

Treatment patterns and outcomes in real-world transplant-ineligible patients newly diagnosed with multiple myeloma.

ANNALS OF HEMATOLOGY, 2021, 100, 1769-1778 dx.doi.org/10.1007/s00277-021-04529-5

Rosiñol L, Oriol A, Rios R, Sureda A, Blanchard MJ, Hernández MT, Martínez-Martínez R, Moraleda JM, Jarque I, Bargay J, Gironella M, de Arriba F, Palomera L, González-Montes Y, Martí JM, Krsnik I, Arguiñano JM, González ME, González AP, Casado LF, López-Anglada L, Paiva B, Mateos MV, San Miguel JF, Lahuerta JJ, Bladé J

Bortezomib, lenalidomide, and dexamethasone as induction therapy prior to autologous transplant in multiple myeloma.

Blood, 2019, 134, 1337-1345 dx.doi.org/10.1182/blood.2019000241

Gassiot S, González Y, Morgades M, Motlló C, Clapés V, Maluquer C, Ibarra G, Abril L, Ribera JM, Oriol A

Response to First Cycle Is the Major Predictor of Long-Term Response to Lenalidomide and Dexamethasone Therapy in Relapsed and Refractory Multiple Myeloma: Can We Spare Patients the Toxicity and Costs of Additional Agents?

Clinical Lymphoma, Myeloma and Leukemia, 2019, 19 dx.doi.org/10.1016/j.clml.2019.05.020

Rodríguez-Otero P, Mateos MV, Martínez-López J, Martín-Calvo N, Hernández MT, Ocio EM, Rosiñol L, Martínez R, Teruel AI, Gutiérrez NC, Bargay J, Bengoechea E, González Y, de Oteyza JP, Gironella M, Encinas C, Martín J, Cabrera C, Palomera L, de Arriba F, Cedena MT, Paiva B, Puig N, Oriol A, Bladé J, Lahuerta JJ, Miguel JFS

Correction: Early myeloma-related death in elderly patients: development of a clinical prognostic score and evaluation of response sustainability role.

Leukemia, 2019, 33, 1056-1056 dx.doi.org/10.1038/s41375-019-0408-x

Rodríguez-Otero P, Mateos MV, Martínez-López J, Hernández MT, Ocio EM, Rosiñol L, Martínez R, Teruel AI, Gutiérrez NC, Bargay J, Bengoechea E, González Y, de Oteyza JP, Gironella M, Nuñez-Córdoba JM, Encinas C, Martín J, Cabrera C, Palomera L, de Arriba F, Cedena MT, Puig N, Oriol A, Paiva B, Bladé J, Lahuerta JJ, San Miguel JF

Predicting long-term disease control in transplant-ineligible patients with multiple myeloma: impact of an MGUS-like signature.

BLOOD CANCER JOURNAL, 2019, 9, 36-36 dx.doi.org/10.1038/s41408-019-0176-x

Rodríguez-Otero P, Mateos MV, Martínez-López J, Martín-Calvo N, Hernández MT, Ocio EM, Rosiñol L, Martínez R, Teruel AI, Gutiérrez NC, Bargay J, Bengoechea E, González Y, de Oteyza JP, Gironella M, Encinas C, Martín J, Cabrera C, Palomera L, de Arriba F, Cedena MT, Paiva B, Puig N, Oriol A, Bladé J, Lahuerta JJ, San Miguel JF

Early myeloma-related death in elderly patients: development of a clinical prognostic score and evaluation of response sustainability role.

Leukemia, 2018, 32, 2427-2434 dx.doi.org/10.1038/s41375-018-0072-6

Rosiñol L, Oriol A, Teruel AI, de la Guía AL, Blanchard M, de la Rubia J, Granell M, Sampol M, Palomera L, González Y, Etxebeste M, Martínez-Martínez R, Hernández MT, de Arriba F, Alegre A, Cibeira M, Mateos M, Martínez-López J, Lahuerta JJ, San Miguel J, Bladé J

Bortezomib and thalidomide maintenance after stem cell transplantation for multiple myeloma: a PETHEMA/GEM trial.

Leukemia, 2017, 31, 1922-1927 dx.doi.org/10.1038/leu.2017.35

Formulari de contacte

Coneix l’IDIBGI!

menu